Cyclopharm (CYC.AX) Akcija Цена

Cyclopharm Цена

ZATVORENO
0,44
​
Tržište je zatvoreno

Prihod je rastao 6,2 % godišnje u poslednjih 19 godina na 32,33 М AUD. Zarada po akciji padala je 14,1 % godišnje u poslednjih 10 godina. neto marža kompanije Cyclopharm sada iznosi -53,3 %, pala sa -28,5 % pre nekoliko godina. Cyclopharm trenutno nudi dividendni prinos od oko 2,27 %. Dividenda je rasla 4,4 % godišnje u poslednjih 8 godina. Medijana analitičke ciljane cene je 1,53 AUD, odnosno iznad trenutnu cenu za 247,7 %. Od 5 analitičara 4 preporučuje kupovinu — ukupni konsenzus je Kupi.

Cena akcije Cyclopharm

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Cyclopharm poslovni model i analiza akcije

Cyclopharm Ltd je australijska kompanija osnovana 1986. godine koja se od tada bavi razvojem inovativnih medicinskih rešenja. Kompanija posluje u oblasti nuklearne medicine i fokusirana je na pružanje dijagnostičkih i terapijskih proizvoda i usluga. Istorija Cyclopharm Ltd-a počinje razvojem generatora Tehnecijum-99m, instrumenta za generisanje radioizotopa koji se koriste u medicinskoj dijagnostici. Od tada, kompanija je proširila svoju ponudu i sada nudi širok spektar proizvoda i usluga. Poslovni model Cyclopharm Ltd-a zasnovan je na istraživanju i razvoju novih rešenja prilagođenih potrebama medicinske zajednice i pacijenata. Kompanija tesno sarađuje sa lekarima, naučnicima i drugim stručnjacima kako bi osigurala da njeni proizvodi i usluge ispunjavaju najviše standarde. Cyclopharm Ltd je podeljena na različite odeljenja radi koordinacije i optimizacije aktivnosti. To uključuju dijagnostiku, terapiju, istraživanje i razvoj, kao i prodaju i marketing. Svako odeljenje tesno sarađuje sa ostalima kako bi se osiguralo da kompanija ostvari svoje ciljeve i pruži optimalnu korisničku podršku. Neki od najpoznatijih proizvoda Cyclopharm Ltd-a uključuju generator Tehnecijum-99m i radiofarmaceutski preparat Technegas. Technegas je gas koji se koristi za snimanje pluća i igra važnu ulogu u dijagnostici oboljenja pluća. Ovaj radiofarmaceutski preparat proizvodi se pomoću generatora Tehnecijum-99m i predstavlja značajan doprinos medicinskom snimanju. Pored toga, Cyclopharm Ltd takođe razvija terapijska rešenja koja se mogu koristiti za lečenje raka i drugih bolesti. To uključuje radiofarmaceutske preparate korišćene u radioterapiji, kao i druga rešenja prilagođena individualnim potrebama pacijenata. Cyclopharm Ltd je takođe aktivno angažovana na poboljšanju i širenju svojih proizvoda i usluga. Kompanija ulaže u istraživanje i razvoj kako bi kreirala inovativna rešenja koja mogu unaprediti medicinsko snimanje i terapiju. Dodatno, kompanija tesno sarađuje sa svojim klijentima kako bi bolje razumela njihove potrebe i ponudila im prilagođena rešenja. U celosti, Cyclopharm Ltd je inovativna i usmerena ka postizanju ciljeva kompanija koja se fokusira na pružanje dijagnostičkih i terapijskih rešenja u oblasti nuklearne medicine. Kompanija ima dugogodišnju istoriju liderstva u ovoj oblasti i nastaviće da bude na čelu razvoja rešenja koja poboljšavaju život pacijenata i medicinskih profesionalaca.

Često postavljana pitanja o akciji Cyclopharm

The business model of Cyclopharm Ltd revolves around the development and commercialization of nuclear medicine products. Cyclopharm is a global leader in the manufacture and distribution of Technegas, a diagnostic imaging agent used for the detection of pulmonary embolism. With a focus on nuclear medicine, Cyclopharm carries out research, development, and production activities to offer innovative solutions for physicians and patients in need of accurate diagnoses. By leveraging their expertise in nuclear medicine, Cyclopharm aims to improve medical imaging techniques and contribute to better patient outcomes worldwide.

Cyclopharm Ltd is primarily active in the medical and healthcare industries.

The main competitors of Cyclopharm Ltd in the market include Progenics Pharmaceuticals, Curium, and Navidea Biopharmaceuticals. These companies also operate in the medical imaging industry and offer products and services that compete with Cyclopharm's offerings.

Cyclopharm Ltd is a leading global radiopharmaceutical company. Established in 1988, Cyclopharm focuses on developing and commercializing innovative nuclear medicine products. The company specializes in technetium generators, used for diagnostic imaging procedures, particularly in lung ventilation and perfusion examinations. With a strong commitment to research and development, Cyclopharm has continued to expand its product portfolio and global presence over the years. The company is headquartered in Sydney, Australia, and has a strong track record in delivering advanced solutions for the medical imaging industry. Cyclopharm Ltd has emerged as a trusted name in the field of radiopharmaceuticals, providing cutting-edge diagnostic tools for better patient care.

Cyclopharm Ltd, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and launched innovative nuclear medicine technologies, including Technegas, a ventilation imaging agent rapidly adopted by the global medical community. Cyclopharm Ltd has established a strong international presence, with distribution networks spanning across multiple continents, allowing them to provide their life-saving products to patients worldwide. The company's commitment to research and development has yielded groundbreaking advancements in diagnostic imaging, revolutionizing the industry. Cyclopharm Ltd continues to strive for excellence, consistently delivering cutting-edge solutions and improving patient outcomes.

Cyclopharm Ltd is primarily present in Australia, New Zealand, and Canada.

Cyclopharm Ltd represents values of innovation, excellence, and patient care. The company maintains a strong corporate philosophy centered around enhancing the field of nuclear medicine through advanced radiopharmaceutical products and services. Cyclopharm Ltd is committed to delivering reliable diagnostic solutions that enable healthcare professionals to effectively diagnose and monitor various diseases. With a focus on research and development, the company strives to introduce groundbreaking technologies and therapies to improve patient outcomes. As a leader in the nuclear medicine industry, Cyclopharm Ltd continuously aims to provide cutting-edge solutions that contribute to the advancement of medical imaging and patient well-being.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 1,53 AUD za akciju Cyclopharm (medijana: 1,53 AUD), što znači +247,7 % u odnosu na poslednju cenu. Konsenzus se zasniva na 5 ocena.

5 analitičara trenutno ocenjuje akciju Cyclopharm: 4 preporučuje kupovinu, 1 držanje i 0 prodaju. Za 2026 analitičari očekuju da Cyclopharm ostvari prihod 37,20 М AUD i zaradu po akciji -0,13 AUD.

Po trenutnom kursu akcija Cyclopharm kotira 0,27 EUR (0,44 AUD).

Cyclopharm Ltd is an Australian medical technology company specializing in X-ray diagnostics. The company offers innovative diagnostic solutions and services for nuclear medicine imaging and therapy planning. The company's main business model focuses on three different divisions: diagnostics, therapy planning, and research. Each division has its own products and services. For diagnostics, Cyclopharm offers Atomlab® Systems, a platform for nuclear medicine imaging that combines PET and SPECT technology. Atomlab® Systems facilitates radiologists and doctors in making critical decisions by providing detailed images of the body to help detect abnormalities and diseases. For therapy planning, Cyclopharm offers Technegas®, a technology that allows for checking lung function and perfusion to support the diagnosis of diseases such as pulmonary embolism. Technegas® is approved by the European Union and the US Food and Drug Administration (FDA) and is considered an important part of clinical practice. In addition, Cyclopharm offers a comprehensive portfolio of radioactive isotopes used in diagnostics and therapy planning. Cyclopharm's research division focuses on developing new diagnostic methods and technologies to improve nuclear medicine imaging and deliver better outcomes for patients. The company collaborates with leading academic institutions and research facilities worldwide to develop innovative diagnostic and treatment options. Cyclopharm is headquartered in Sydney, Australia, and distributes its products and services globally. The company employs approximately 100 employees and is listed on the Australian stock exchange. Cyclopharm's business model is based on offering innovative and high-quality diagnostic solutions tailored to the needs of radiologists, doctors, and patients. By combining PET and SPECT technology, Technegas technology, and an isotope portfolio, Cyclopharm has a unique position in nuclear medicine imaging. The company is also committed to sustainability and strives for environmental compatibility and safety in all aspects of its products and services. It works closely with regulatory authorities to ensure compliance with all relevant regulations and guidelines. Overall, Cyclopharm is a leading provider of diagnostic solutions and services in nuclear medicine imaging. Through innovative technology and a strong focus on research and development, the company will continue to play an important role in the industry and contribute to improving healthcare worldwide.

očekivana prihod od Cyclopharm je 37,20 М AUD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Cyclopharm je -14,20 М AUD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Cyclopharm je trenutno -3,41. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Cyclopharm.

Odnos cene i prihoda (KUV) za Cyclopharm je trenutno 1,30. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Cyclopharm.

Eulpool score kvaliteta za Cyclopharm je 5/10.

ISIN za Cyclopharm je AU000000CYC5. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

Ticker za Cyclopharm je CYC.AX. Simbol tikera se koristi za trgovinu akcijama Cyclopharm na berzanskom tržištu.

Фер вредностTerminal
0,37 AUD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Медицинска опрема и понуде
Број акција
Запослени
Приход по запосленом
897.923,78 AUD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт cyclopharm.com.au
Земља
Аустралија
Валута
AUD
Јавна понуда
18. јан 2007.
ISIN
AU000000CYC5
CUSIP
Q3079G106
SEDOL
B1LSYZ2
Тржишна капитализација
45,28 М AUDMicro Cap
Опсег од 52 недеље
AAQS
5 / 10
PEG
0,08
P/E однос
P/Ee 2026
-3,41
P/Ee 2027
-5,34
P/Ee 2028
-12,05
P/S
P/Se
1,30
EV/EBIT
—
P/B однос
1,67
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-40,97 %
Дивиденда
Прinos од дивиденде
0,00 %
Процењени принос од дивиденде
2,27 %
Стопа исплате
47,33 %
Раст дивиденде Ø5Y
—
Дивиденде по години
2
Дивиденда исплаћена од
0 година
Дивиденда није смањена од
0 година
Дивиденда повећана од
0 година
Порез на дивиденде
30,00 %
Zadnje ažurirano 20. нов 2026. 03:25

Cyclopharm FIGI

CYC:AU · BBG000QFS006CYC:AT · BBG000QFS060CYC:AH · BBG002F3MM27CYCMF:US · BBG00ZTHNCL8CYCMF:PQ · BBG00ZTHND18CYCMF:UV · BBG00ZTHND27

Sve ključne metrke i detaljne analize Cyclopharm u dubinskoj analizi

Naša analiza akcija za akciju Cyclopharm uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Cyclopharm. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: